32 results about "Telithromycin" patented technology

The present invention relates to the process for the preparation of compounds of formula (I) or its pharmaceutically acceptable saltswherein, R is

This disclosure describes the use of azithromycin, roxithromycin, and telithromycin, including derivatives thereof, as senolytic drugs. BrdU was used to induce senescence in model human fibroblast cell lines. Also disclosed are methods for screening compounds for senolytic activity. The SRB assay was used to measure cell viability through protein content. Azithromycin roxithromycin, and telithromycin, clinically-approved pharmaceuticals, were found to be senolytic drugs. However, the closely-related parent compound, erythromycin, showed no senolytic activity. Azithromycin strongly induced both aerobic glycolysis and autophagy in human fibroblasts, but showed bi-phasic effects including on mitochondrial oxygen consumption rates with inhibitory activity at 50 muM and stimulatory activity at 100 muM. The xCELLigence real-time assay system showed that azithromycin preferentially targets senescent cells, removing approximately 97% (nearly a 25-fold reduction in senescent cells).

The invention discloses a new method for preparing macrolides semi-synthesizing antibiotic tallysomycin. The mother core part uses 6-methoxy bristacin as raw material, which is dewatered on the effect of the base after dewatering, acylating, re-etherification and oxidant, and then it reacts with the carbonyl diimidazole to obtain the intermediate (VI); the lateral chain part uses 3-acetyl pyridine as raw material and is hydrolyzed after bromide and reacting with the hexamine, then it ringed with the potassium sulfocyanide and reacts with the N-(4-bromide butyl)-phthalimide on base condition after the effect of diluted nitric acid and then it is hydrazinolysized to obtain the lateral chain (XIII); the intermediate (VI) reacts with the lateral chain (XIII) to synthesize the tallysomycin.

The invention discloses a method for preparing a porphyromonas gingivalis culture medium for plaque specimens. The method is characterized in that the formula for preparing 1000ml of culture medium contains malt extract, egg protein fluid, heme chloride solution, vitamin K1 ethanol solution, magnesium citrate, agar, synercid, telithromycin, linezolid and asparagines, and distilled water added to 1000ml. The preparation method of the optimized formula comprises the steps of dissolving the malt extract, the egg protein fluid, chlorhematin, agar, magnesium citrate, calcium citrate tetrahydrate, synercid, garlic extract juice and L-cysteine into rhizoma polygonati boiling liquid; evenly mixing, fixing the volume and charging after sterilizing. Compared with the prior art, the porphyromonas gingivalis culture medium has the characteristics of detection reliability and high porphyromonas gingivalis separation rate.

The invention discloses application of azithromycin and telithromycin in anti-ebola-virus infection, including application of azithromycin or / and telithromycin in prevention or treatment of ebola virus infection or combined application of azithromycin or / and telithromycin with other anti-virus drugs.

The present invention relates to stable amorphous 3-De[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribohexopyranosyl)oxy]-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl[[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]erythromycin (telithromycin), methods for the preparation thereof, the use of stable amorphous telithromycin in the treatment of bacterial infections and to pharmaceutical compositions comprising stable amorphous telithromycin.

This invention relates to an eye use transmission system of macrolide type antibiotic hyaluronic acid natrium. The goal of this invention is to provide a macrolide type antibiotic eye use medicine preparation with carrier is hyaluronic acid or its salt. It is used to cure germ eye region infection. The macrolide type antibiotic in this invention includes antibiotic that has 14 yuan,15yuan, 16yuan large ring construction features , for example, natural antibiotic bring by streptomycete erythromycin, josamycin, spiramycin, medemycin etc. and semisynthesis derivant from by structure modification of natural antibiotic, such as roxithromycin, azithromycin, clarithromycin, rokitamycin, telithromycin.

The invention discloses a prevention and cure chemical agent for sisal hemp mealybug. The chemical agent is prepared from the following raw materials in parts by weight: 1 to 2 parts of kaolin, 0.5 to1.6 parts of konjac glucomannan, 4 to 8 parts of sepiolite, 0.2 to 0.4 part of vegetable oil, 3 to 6 parts of calcium acetate, 4 to 8 parts of potassium dihydrogen phosphate, 2 to 4 parts of biological surfactant, 6 to 15 parts of fungus concentrate, 3 to 5 parts of fatty alcohol-polyoxyethylene ether, 2 to 6 parts of alkyl polyoxyethylene ether, 1 to 3 parts of sucrose fatty acid ester, 0.5 to 1.6 parts of r-amino butyrate, and 0.2 to 0.6 part of telithromycin. After being sprayed, the chemical agent is adhered onto the surface of mealybug, the components of the chemical agent such as the biological surfactant, fatty alcohol-polyoxyethylene ether, alkyl polyoxyethylene ether and the like can damage the shell of the mealybug, so that active ingredients such as the fungus concentrate can enter the body of the mealybug so as to kill the mealybug, and the killing effect is good; and the konjac glucomannan, the kaolin and the sepiolite in the chemical agent wraps the fungus concentrate, so that the chemical effect period can be prolonged.